Sclerostin Small Molecule Inhibitor

About OssiFi Therapeutics

OssiFi Therapeutics is a privately held, preclinical-stage biotech founded in 2019 and headquartered in the Boston area, with an operational office in Overland Park, KS. The company is developing best-in-class small molecule inhibitors of sclerostin to build bone, aiming for safer and more effective therapies than existing biologics. Its strategy combines therapeutic and device development to target neurogenic low back pain, fracture care, and osteoporosis, leveraging a management team with deep drug development expertise and a network of key clinical advisors in orthopedics and spine care.

Therapeutic Areas